naltrexone extended release Vivitrol
Selected indexed studies
- Extended-release intramuscular naltrexone. (Drugs, 2006) [PMID:16978037]
- Oral vs Extended-Release Injectable Naltrexone for Hospitalized Patients With Alcohol Use Disorder: A Randomized Clinical Trial. (JAMA Intern Med, 2025) [PMID:40257810]
- AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. (Gastroenterology, 2022) [PMID:36273831]
_Worker-drafted node — pending editorial review._
Connections
naltrexone extended release Vivitrol is a side effect of
Sources
- Oral vs Extended-Release Injectable Naltrexone for Hospitalized Patients With Alcohol Use Disorder: A Randomized Clinical Trial. (2025) pubmed
- Bupropion and Naltrexone in Methamphetamine Use Disorder. (2021) pubmed
- Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. (2018) pubmed
- AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. (2022) pubmed
- Extended-release intramuscular naltrexone. (2006) pubmed
- Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients. (2013) pubmed
- Pharmacokinetics of Oral and Extended-release Naltrexone in Pregnant and Lactating Individuals and their Infants. (2026) pubmed
- Effect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis. (2022) pubmed
- Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. (2018) pubmed
- Engineered PLGA microspheres for extended-release of naltrexone: in vitro, in vivo, and IVIVR. (2023) pubmed